Welcome to our dedicated page for Aldeyra Therapeutics SEC filings (Ticker: ALDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aldeyra Therapeutics SEC filings document a biotechnology issuer focused on investigational therapies for immune-mediated diseases and formal disclosures tied to its RASP modulator pipeline. Recent 8-K reports furnish press releases and corporate presentations covering reproxalap regulatory review, clinical and preclinical program updates, pipeline prioritization, and FDA-related disclosures for dry eye disease.
The filing record also covers governance and capital-structure matters, including definitive proxy materials for annual meeting proposals and director elections, board-transition disclosures, and the payoff and termination of the Hercules Credit Facility. These filings group Aldeyra's public-company record around operating updates, risk and forward-looking-statement disclosures, stockholder voting matters, and financing arrangements.
Director Nancy Miller-Rich received two stock option awards from Aldeyra Therapeutics, Inc. These options allow her to buy 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share, with an expiration date of June 8, 2036.
Each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date. Vesting is conditioned on her continued service on the Board of Directors and, for the larger grant, on the Compensation Committee through the applicable vesting date. These are compensation-related grants, not open-market purchases or sales.
Aldeyra Therapeutics director Douglas Richard received new stock option awards. The Form 4 shows three option grants to buy Common Stock at an exercise price of $1.72 per share, covering 2,323, 19,909, and 70,000 underlying shares, respectively.
Each grant becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided he continues serving in the specified roles: as a member of the Board, as Chairperson of the Board, and as a member of the Nominating/Corporate Governance Committee.
Aldeyra Therapeutics director Gary M. Phillips received three stock option grants. On the reported date, he was awarded options to buy 70,000, 6,636 and 4,977 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable on the one-year anniversary of the grant date, if he continues serving on the Board and its Compensation and Audit Committees as applicable.
Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation. One option for 2,323 shares of common stock and another for 70,000 shares were granted with an exercise price of $1.72 per share and an expiration date of June 8, 2036.
Each grant becomes exercisable for 100% of the underlying shares on the one-year anniversary of the grant date. Vesting is conditioned on Clark providing continuous service, respectively, as a member of the Board of Directors and of the Nominating/Corporate Governance Committee through the applicable vesting date.
Aldeyra Therapeutics director Neal Walker received two new stock option grants. On the grant date, he was awarded options for 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share. Each grant becomes fully exercisable one year after grant, contingent on his continued Board and Compensation Committee service.
Aldeyra Therapeutics director Ben Bronstein received three stock option awards, each covering rights to buy common stock at an exercise price of $1.72 per share. The grants cover 4,977, 5,309, and 70,000 underlying shares, respectively, and are reported as compensation-related acquisitions rather than market purchases.
According to the filing, each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided Bronstein continues serving on the Board of Directors and, for two grants, on the Nominating/Corporate Governance and Audit Committees through the applicable vesting dates. All options are scheduled to expire on June 8, 2036 if not exercised.
Aldeyra Therapeutics, Inc. director Darlene M. Deptula‑Hicks received two stock option grants to acquire common stock at an exercise price of $1.72 per share.
One option for 9,756 shares vests in equal annual installments over three years after June 9, 2026. A second option for 84,557 shares becomes exercisable for all shares on the one‑year anniversary of the grant date if she continues serving on the Audit Committee. Both options expire on June 8, 2036.
Aldeyra Therapeutics, Inc. director Darlene M. Deptula-Hicks filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not report any stock transactions or option exercises; it simply establishes her status as a reporting person at the company.
Aldeyra Therapeutics, Inc. appointed Darlene Deptula-Hicks as a Class III director and Chair of the audit committee following its 2026 annual stockholder meeting. She is considered independent and qualifies as an audit committee financial expert under SEC and Nasdaq rules.
As a new non-employee director, she received a stock option for 94,313 common shares that vests over three years, plus annual cash fees for board and audit chair service and eligibility for additional annual option grants. Stockholders elected Todd C. Brady, M.D., Ph.D., ratified BDO USA, P.C. as auditor for 2026, and approved executive compensation on an advisory basis.
Aldeyra Therapeutics, Inc. President and CEO Todd C. Brady reported an open-market purchase of common stock. He bought 250,000 shares of Aldeyra common stock at a weighted average price of $1.6738 per share in transactions on June 3, 2026. Following this purchase, he directly owns 1,721,298 shares of Aldeyra common stock. The footnote explains that the shares were acquired in multiple trades at prices ranging from $1.64 to $1.70 per share.